Some European countries take more than twice as long as others to decide whether to provide reimbursement for new cancer medicines following approval by the European Medicines Agency, according to a study that will be presented at the European Society of Medical Oncology, a gathering of researchers that got underway on Friday in Munich.

In reaching their conclusions, the researchers identified all of the new cancer drugs that were approved for solid tumors by the EMA between January 2007 and December 2016. From there, they tracked the time between EMA approval for each drug and reimbursement decisions made by health authorities in four European countries: England, France, Germany, and Scotland.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy